GLP-1 drugs are being studied in a growing number of indications, and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has expanded ...
Novo Nordisk drug Ozempic, already a blockbuster seller in type 2 diabetes, now has clinical trial results showing it reduced the risk of kidney disease complications by 24%. The company is planning U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback